{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:28:55Z","timestamp":1793053735683,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Multiparametric MRI (mpMRI) enhances prostate cancer (PCa) detection, especially when combined with targeted or MRI\u2013ultrasound fusion biopsy. However, PI-RADS 3 lesions remain diagnostically indeterminate, with variable malignancy risk and heterogeneous clinical management. This study aims to identify clinical and radiological predictors of PCa and clinically significant PCa (csPCa) in patients with PI-RADS 3 lesions in order to enhance risk stratification. By disentangling patient- and disease-specific characteristics from imaging findings, the study evaluates their independent prognostic value. The primary objective is to validate non-imaging parameters as reliable tools for risk stratification in indeterminate cases, thereby supporting clinical decision-making when radiological assessment alone is inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, 671 patients with 981 PI-RADS 3 lesions underwent mpMRI and MRI\u2013ultrasound fusion-guided transrectal biopsy, including both targeted and systematic cores. Histopathological evaluation was based on ISUP grading. Logistic regression models were used to assess associations between clinical\/radiological factors and biopsy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall cancer detection per lesion was 36.9%, with csPCa detected in 15.8% of lesions and 42.8% of positive biopsies. PSA density emerged as the strongest predictor of both PCa and csPCa, while prostate volume was inversely associated. csPCa was more commonly found in patients undergoing primary biopsy and those with posterior lesion localization. In selected low-risk groups, csPCa detection was rare, suggesting potential to avoid unnecessary biopsies, with specificity reaching up to 90%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overlapping benign conditions and interobserver variability contribute to uncertainty in the interpretation of PI-RADS 3 lesions with regard to the indication for biopsy. PSA density and clinical context support risk-adapted decision-making, aligning with current guideline recommendations. A personalized approach is recommended to balance the risks of under- and overdiagnosis in managing PI-RADS 3 lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-01986-2","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:19:43Z","timestamp":1761977983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["To biopsy or not biopsy, that is the question - PI-RADS 3 prostate lesions \u2013 validation of clinical and radiological parameters for biopsy decision-making"],"prefix":"10.1186","volume":"25","author":[{"given":"Toni","family":"Franz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Sicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Lueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Phuc","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Spinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Christian","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schaudinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Liatsikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Stolzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"1986_CR1","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid. 2025. ISBN 978-94-92671-29-5. EAU Guidelines Office, Arnhem, The Netherlands. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/."},{"issue":"1","key":"1986_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JU.0000000000003492","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early detection of prostate cancer: AUA\/SUO guideline Part II: considerations for a prostate biopsy. J Urol. 2023;210(1):54\u201363. https:\/\/doi.org\/10.1097\/JU.0000000000003492.","journal-title":"J Urol"},{"issue":"3","key":"1986_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/mou.0b013e328329a33e","volume":"19","author":"AR Patel","year":"2009","unstructured":"Patel AR, Jones JS. Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol. 2009;19(3):232\u20137. https:\/\/doi.org\/10.1097\/mou.0b013e328329a33e.","journal-title":"Curr Opin Urol"},{"issue":"6","key":"1986_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","volume":"68","author":"JJ F\u00fctterer","year":"2015","unstructured":"F\u00fctterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.013.","journal-title":"Eur Urol"},{"issue":"4","key":"1986_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","volume":"313","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390\u20137. https:\/\/doi.org\/10.1001\/jama.2014.17942.","journal-title":"JAMA"},{"issue":"4","key":"1986_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.juro.2011.05.078","volume":"186","author":"PA Pinto","year":"2011","unstructured":"Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, et al. Magnetic resonance imaging\/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011;186(4):1281\u20135. https:\/\/doi.org\/10.1016\/j.juro.2011.05.078.","journal-title":"J Urol"},{"key":"1986_CR7","doi-asserted-by":"publisher","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. Eur Urol. 2016;69(1):16\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.052. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.","DOI":"10.1016\/j.eururo.2015.08.052"},{"issue":"6","key":"1986_CR8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.eururo.2011.02.034","volume":"59","author":"A Sciarra","year":"2011","unstructured":"Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59(6):962\u201377. https:\/\/doi.org\/10.1016\/j.eururo.2011.02.034. Epub 2011 Feb 23. PMID: 21367519.","journal-title":"Eur Urol"},{"key":"1986_CR9","doi-asserted-by":"publisher","unstructured":"Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902-9. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.047 Epub 2012 Feb 1. PMID: 22325447.","DOI":"10.1016\/j.eururo.2012.01.047"},{"issue":"1","key":"1986_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.eururo.2015.03.041","volume":"69","author":"E Baco","year":"2016","unstructured":"Baco E, Rud E, Eri L, Moen G, Vlatkovic L, Svindland A, et al. A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy. Eur Urol. 2016;69(1):149\u201356. https:\/\/doi.org\/10.1016\/j.eururo.2015.03.041.","journal-title":"Eur Urol"},{"issue":"3","key":"1986_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/pros.24286","volume":"82","author":"B Kaufmann","year":"2022","unstructured":"Kaufmann B, Saba K, Schmidli TS, Stutz S, Bissig L, Britschgi AJ, et al. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy. Prostate. 2022;82(3):388\u201396. https:\/\/doi.org\/10.1002\/pros.24286.","journal-title":"Prostate"},{"key":"1986_CR12","doi-asserted-by":"publisher","unstructured":"Rouvi\u00e8re O, Puech P, Renard-Penna R, Claudon M, Roy C, M\u00e8ge-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-first): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(18)30569-2.","DOI":"10.1016\/S1470-2045(18)30569-2"},{"issue":"3","key":"1986_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102853","volume":"35","author":"T Long Depaquit","year":"2025","unstructured":"Long Depaquit T, Uleri A, Peyrottes A, Corral R, Toledano H, Chiron P, et al. PI-RADS 3 MRI lesions: are biopsies still necessary? The French Journal of Urology. 2025;35(3):102853. https:\/\/doi.org\/10.1016\/j.fjurol.2024.102853.","journal-title":"The French Journal of Urology"},{"issue":"17","key":"1986_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173084","volume":"16","author":"F Palmisano","year":"2024","unstructured":"Palmisano F, Lorusso V, Legnani R, Martorello V, Nedbal C, Tramanzoli P, et al. Analysis of the performance and accuracy of a PSA and PSA ratio-based nomogram to predict the probability of prostate cancer in a cohort of patients with PIRADS 3 findings at multiparametric magnetic resonance imaging. Cancers (Basel). 2024;16(17):3084. https:\/\/doi.org\/10.3390\/cancers16173084.","journal-title":"Cancers (Basel)"},{"key":"1986_CR15","doi-asserted-by":"publisher","unstructured":"Kortenbach KC, L\u00f8gager V, Thomsen HS, Boesen L. Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies. Abdom Radiol (NY). 2023;48(2):688\u2013693.\u00a0https:\/\/doi.org\/10.1007\/s00261-022-03720-0 . Epub 2022 Nov 1. PMCID: PMC9902318","DOI":"10.1007\/s00261-022-03720-0"},{"issue":"11","key":"1986_CR16","doi-asserted-by":"publisher","first-page":"490.e1","DOI":"10.1016\/j.urolonc.2022.08.003","volume":"40","author":"J Drevik","year":"2022","unstructured":"Drevik J, Dalimov Z, Uzzo R, Danella J, Guzzo T, Belkoff L, et al. Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative. Urol Oncol. 2022;40(11):490.e1-490.e6. https:\/\/doi.org\/10.1016\/j.urolonc.2022.08.003.","journal-title":"Urol Oncol"},{"issue":"18","key":"1986_CR17","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1002\/cncr.34355","volume":"128","author":"AM Fang","year":"2022","unstructured":"Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, et al. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Cancer. 2022;128(18):3287\u201396. https:\/\/doi.org\/10.1002\/cncr.34355.","journal-title":"Cancer"},{"key":"1986_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejrad.2019.02.031","volume":"114","author":"I Hermie","year":"2019","unstructured":"Hermie I, Van Besien J, De Visschere P, Lumen N, Decaestecker K. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center. Eur J Radiol. 2019;114:92\u20138. https:\/\/doi.org\/10.1016\/j.ejrad.2019.02.031.","journal-title":"Eur J Radiol"},{"issue":"3","key":"1986_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4258","volume":"7","author":"A Haj-Mirzaian","year":"2024","unstructured":"Haj-Mirzaian A, Burk KS, Lacson R, Glazer DI, Saini S, Kibel AS, et al. Magnetic resonance imaging, clinical, and biopsy findings in suspected prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(3):e244258. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.4258.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1986_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-04776-x","volume":"42","author":"J Kwe","year":"2024","unstructured":"Kwe J, Baunacke M, Boehm K, Platzek I, Thomas C, Borkowetz A. PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions. World J Urol. 2024;42(1):84. https:\/\/doi.org\/10.1007\/s00345-024-04776-x.","journal-title":"World J Urol"},{"issue":"11","key":"1986_CR21","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.3390\/curroncol31110503","volume":"31","author":"LJ Jensen","year":"2024","unstructured":"Jensen LJ, Kim D, Elgeti T, Steffen IG, Schaafs L-A, Haas M, et al. Detecting clinically significant prostate cancer in PI-RADS 3 lesions using T2w-derived radiomics feature maps in 3T prostate MRI. Curr Oncol. 2024;31(11):6814\u201328. https:\/\/doi.org\/10.3390\/curroncol31110503.","journal-title":"Curr Oncol"},{"key":"1986_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bju.15277","volume":"127","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, et al. Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int. 2021;127:175. https:\/\/doi.org\/10.1111\/bju.15277.","journal-title":"BJU Int"},{"issue":"2","key":"1986_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244\u201352. https:\/\/doi.org\/10.1097\/PAS.0000000000000530.","journal-title":"Am J Surg Pathol"},{"key":"1986_CR24","doi-asserted-by":"publisher","unstructured":"Esengur OT, Yilmaz EC, Ozyoruk KB, Chen A, Lay NS, Gelikman DG, et al. Multimodal approach to optimize biopsy decision-making for PI-RADS 3 lesions on multiparametric MRI. Clin Imaging. 2025;117. https:\/\/doi.org\/10.1016\/j.clinimag.2024.110363. 110363.Epub 2024 Nov 19.","DOI":"10.1016\/j.clinimag.2024.110363"},{"issue":"3","key":"1986_CR25","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13959","volume":"26","author":"K Mate","year":"2023","unstructured":"Mate K, Nedjim S, Bellucci S, Boucault C, Ghaffar N, Constantini T, et al. Prostate biopsy approach and complication rates. Oncol Lett. 2023;26(3):375. https:\/\/doi.org\/10.3892\/ol.2023.13959.","journal-title":"Oncol Lett"},{"key":"1986_CR26","doi-asserted-by":"publisher","unstructured":"Sonmez G, Tombul ST, Demirtas T, Demirtas A. Clinical factors for predicting malignancy in patients with PSA\u2009<\u200910 ng\/mL and PI-RADS 3 lesions. Asia Pac J Clin Oncol. 2021;17(2):e94-e99. https:\/\/doi.org\/10.1111\/ajco.13347.\u00a0Epub 2020 Aug 10. PMID: 32779392","DOI":"10.1111\/ajco.13347"},{"issue":"2","key":"1986_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.7812\/TPP\/23.178","volume":"28","author":"EM Jyo","year":"2024","unstructured":"Jyo EM, Yoon HC, Burton B. The added value of prostate magnetic resonance imaging to patient selection. Perm J. 2024;28(2):86\u201392. https:\/\/doi.org\/10.7812\/TPP\/23.178.","journal-title":"Perm J"},{"issue":"3","key":"1986_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.21873\/invivo.11075","volume":"31","author":"P Pepe","year":"2017","unstructured":"Pepe P, D\u2019Urso D, Garufi A, Priolo G, Pennisi M, Russo G, et al. Multiparametric MRI apparent diffusion coefficient (ADC) accuracy in diagnosing clinically significant prostate cancer. In Vivo. 2017;31(3):415\u20138. https:\/\/doi.org\/10.21873\/invivo.11075.","journal-title":"In Vivo"},{"issue":"6","key":"1986_CR29","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.24.31991","volume":"223","author":"N Schieda","year":"2024","unstructured":"Schieda N, Patni Z, Morash C, Md TAF, Breau RH. MRI-directed fusion prostate biopsy strategies: comparison of targeted biopsy alone versus targeted with ipsilateral or bilateral systematic biopsy, by MpMRI or BpMRI targeting. AJR Am J Roentgenol. 2024;223(6):e2431991. https:\/\/doi.org\/10.2214\/ajr.24.31991.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"1986_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/bju.16831","volume":"136","author":"N Schieda","year":"2025","unstructured":"Schieda N, Morash C, Lavallee LT, Flood TA, Cagiannos I, Elzayat E, et al. Prostate cancer detection by MRI-ultrasonography fusion transperineal vs transrectal biopsy: a randomised control trial. BJU Int. 2025;136(4):698\u2013706. https:\/\/doi.org\/10.1111\/bju.16831.","journal-title":"BJU Int"},{"issue":"4","key":"1986_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040623","volume":"11","author":"S Merat","year":"2021","unstructured":"Merat S, Bl\u00fcmlein T, Klarh\u00f6fer M, Nickel D, Singer G, Z\u00f6llner FG, et al. Impact of chronic prostatitis on the PI-RADS score 3: proposal for the addition of a novel binary suffix. Diagnostics. 2021;11(4):623. https:\/\/doi.org\/10.3390\/diagnostics11040623.","journal-title":"Diagnostics"},{"issue":"1","key":"1986_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00330-022-08947-5","volume":"33","author":"F Giganti","year":"2023","unstructured":"Giganti F, Cole AP, Fennessy FM, Clinton T, Moreira PLDF, Bernardes MC, Westin CF, Krishnaswamy D, Fedorov A, Wollin DA, Langbein B, Frego N, Labban M, Badaoui JS, Chang SL, Briggs LG, Tokuda J, Ambrosi A, Kirkham A, Emberton M, Kasivisvanathan V, Moore CM, Allen C, Tempany CM. Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas gourtsoyiannis teaching fellowship. Eur Radiol. 2023;33(1):461\u201371. https:\/\/doi.org\/10.1007\/s00330-022-08947-5. Epub 2022 Jun 30. PMID: 35771247; PMCID: PMC9244244.","journal-title":"Eur Radiol"},{"issue":"2","key":"1986_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4081\/aiua.2021.2.139","volume":"93","author":"P Pepe","year":"2021","unstructured":"Pepe P, Candiano G, Pepe L, Pennisi M, Fraggetta F. MpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: our experience in 950 cases. Arch Ital Urol Androl. 2021;93(2):139\u201342. https:\/\/doi.org\/10.4081\/aiua.2021.2.139.","journal-title":"Arch Ital Urol Androl"},{"issue":"4","key":"1986_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10334-022-01031-5","volume":"35","author":"DK Dwivedi","year":"2022","unstructured":"Dwivedi DK, Jagannathan NR. Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI. MAGMA. 2022;35(4):587\u2013608. https:\/\/doi.org\/10.1007\/s10334-022-01031-5.","journal-title":"MAGMA"},{"issue":"5","key":"1986_CR35","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/jmri.25850","volume":"47","author":"DK Dwivedi","year":"2018","unstructured":"Dwivedi DK, Kumar R, Dwivedi AK, Bora GS, Thulkar S, Sharma S, et al. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4\u201310 ng\/mL. J Magn Reson Imaging. 2018;47(5):1227\u201336. https:\/\/doi.org\/10.1002\/jmri.25850.","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"1986_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41585-022-00648-4","volume":"20","author":"T Barrett","year":"2023","unstructured":"Barrett T, de Rooij M, Giganti F, Allen C, Barentsz JO, Padhani AR. Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nat Rev Urol. 2023;20(1):9\u201322. https:\/\/doi.org\/10.1038\/s41585-022-00648-4.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1986_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41391-024-00872-6","volume":"28","author":"G Mjaess","year":"2025","unstructured":"Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, et al. Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions. Prostate Cancer Prostatic Dis. 2025;28(1):173\u20139. https:\/\/doi.org\/10.1038\/s41391-024-00872-6.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"1986_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/pros.24840","volume":"85","author":"A Ayranci","year":"2025","unstructured":"Ayranci A, Caglar U, Yazili HB, Erdal FS, Erbin A, Sarilar O, et al. PSA density and lesion volume: key factors in avoiding unnecessary biopsies for PI-RADS 3 lesions. Prostate. 2025;85(4):385\u201390. https:\/\/doi.org\/10.1002\/pros.24840.","journal-title":"Prostate"},{"issue":"6","key":"1986_CR39","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/j.clgc.2020.04.006","volume":"18","author":"M Roscigno","year":"2020","unstructured":"Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, Naspro R, Nicolai M, La Croce G, Aljoulani M, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF. The use of multiparametric magnetic resonance imaging for Follow-up of patients included in active surveillance Protocol. Can PSA density discriminate patients at different risk of reclassification? Clin Genitourin Cancer. 2020;18(6):e698\u2013704. https:\/\/doi.org\/10.1016\/j.clgc.2020.04.006. Epub 2020 May 4. PMID: 32493676.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"1986_CR40","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","volume":"34","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ, Thijssen LCP, Asbach P, Barrett T, et al. PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol. 2024;34(11):7068\u201379. https:\/\/doi.org\/10.1007\/s00330-024-10795-4.","journal-title":"Eur Radiol"},{"issue":"12","key":"1986_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123473","volume":"11","author":"P Pepe","year":"2022","unstructured":"Pepe P, Roscigno M, Pepe L, Panella P, Tamburo M, Marletta G, et al. Could 68Ga-PSMA PET\/CT evaluation reduce the number of scheduled prostate biopsies in men enrolled in active surveillance protocols? J Clin Med. 2022;11(12):3473. https:\/\/doi.org\/10.3390\/jcm11123473.","journal-title":"J Clin Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01986-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:35:19Z","timestamp":1781613319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-01986-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01986-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7463239\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The submitted manuscript meets all criteria of the ICMJE recommendations and COPE guidelines. The requirement for ethical approval was waived by the Ethics Committee at the Medical Faculty of the University of Leipzig. Reference number: 280\/25-ek, approved initially on 19\/08\/2025. \u201cThere are no ethical and scientific concerns.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}